Prophylactic Treatment With Atorvastatin for Episodic Migraine.

ClinicalTrials.gov ID

NCT06248671

Lead Sponsor

St. Olavs HospitalOTHER

Overall Status

Recruiting

Study Type

Interventional

Phase

Phase 2

Enrollment

450Estimated

Last Update Posted

Jul 14, 2026Actual

Start Date

May 1, 2024Actual

Primary Completion Date

Dec 31, 2028Estimated

Completion Date

Feb 28, 2029Estimated

Official Title

EpisodicStatinMig. A Multicentre, Triple Blind, Placebo Controlled, Parallel Group Study of Atorvastatin in Episodic Migraine

Brief Summary

The main objective of this study is to see whether the favorable preventative effect of Atorvastatin 40mg per day in episodic migraine, that was found previously in three smaller randomized controlled cross-over studies, can be confirmed in a larger, multicenter, randomized controlled parallel group study. In addition it will be investigated whether 1) there is an effect of a daily dose of 20mg Atorvastatin, 2) whether the favorable side effect profile, seen in previous studies, can be confirmed, and whether it is even better with the smaller dose, and 3) estimating the cost of Atorvastatin treatment, considering cost of medicine, cost of acute attack medicine, and cost of lost worktime.

• Episodic Migraine

• Atorvastatin 40mg
• Placebo
• Atorvastatin 20mg

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

Yes

Eligibility Criteria

Inclusion Criteria:

• Age 18 to 65 years.
• Signed informed consent.
• Episodic migraine with or without aura according to ICHD-3 criteria.
• At inclusion, patients should retrospectively have from 4 to 14 migraine attacks per month during the last 3 months. This frequency must be confirmed in the headache diary before randomisation to treatment.
• Debut of migraine at least one year prior to inclusion based on information in the patient record or by careful examination of previous headache history.
• Start of migraine before 50 years.
• No use of other migraine prophylactics during the study.
• For women of child-bearing potential, there must be no pregnancy or planned pregnancy during the study period, and use of highly effective contraception.

After the baseline period, just before randomisation to the study drug, inclusion criteria will be evaluated once more, and the headache diary will be evaluated. If there are, according to the headache diary, fewer attacks than 4 or more than 14 per month, the baseline period can be extended to 8 weeks, and the patient can be randomized to a treatment then if there is a mean of 4-14 attacks per 4 weeks during the 8-week's period.

Exclusion Criteria:

• Interval headache not distinguishable from migraine.
• Chronic migraine, chronic tension-type headache, medication overuse headache or other headache occurring on ≥ 15 days/month.
• Pregnancy, planning to get pregnant, inability to use contraceptives, and lactating.
• Clinical information on or signs of cholestasis or decreased hepatic or renal function.
• High degree of comorbidity and/or frailty associated with reduced life expectancy or high likelihood of hospitalization, at the discretion of the investigator.
• Hypersensitivity to statins or previous use of statins.
• History of angioneurotic oedema.
• Use of medicines for migraine prophylaxis less than 4 weeks, or of botulinum toxin less than 16 weeks, prior to start of study.
• Current use of antiviral treatment against hepatitis C.
• Significant psychiatric illness.
• Having tried ≥ 3 prophylactic drugs against migraine during the last 10 years.
• Requiring detoxification from acute medication (triptans, opioids).
• Consistently failing to respond to any acute migraine medication.
• Alcohol or illicit drug dependence.
• Inability to understand study procedures and to comply with them for the entire length of the study.
• Treatment for hypothyroidism.
• Lactose intolerance.

Primary Purpose

Prevention

Allocation

Randomized

Interventional Model

Parallel Assignment

Masking

Triple

Lead Sponsor

St. Olavs HospitalOTHER

Collaborators

Haukeland University HospitalOTHER

University Hospital of North NorwayOTHER

University Hospital, AkershusOTHER

Ullevaal University HospitalOTHER

a.h.aamodt@medisin.uio.no

bendik.s.winsvold@gmail.com

linn.steffensen@unn.no

lise.r.oie@ntnu.no41419596 ext. 0047

• Prophylactic Treatment With Atorvastatin for Chronic Migraine (ChronicStatinMig)

  NCT06485336

  RecruitingInterventionalPhase 2Updated Jul 20, 2026
• Statin/Vitamin D & Migraine Study

  NCT01225263

  CompletedInterventionalPhase 2Updated Jan 26, 2016
• Study to Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine

  NCT03700320

  CompletedInterventionalPhase 3Updated Jun 15, 2021
• Efficacy, Safety, and Tolerability of Atogepant for the Prevention of Chronic Migraine

  NCT03855137

  CompletedInterventionalPhase 3Updated Feb 14, 2023
• Atogepant for Prophylaxis of Migraine in Participants Who Failed Previous Oral Prophylactic Treatments.

  NCT04740827

  CompletedInterventionalPhase 3Updated Sep 21, 2023
• 12-Week Placebo-controlled Study of Atogepant for the Preventive Treatment of Migraine in Participants With Episodic Migraine

  NCT03777059

  CompletedInterventionalPhase 3Updated Jul 9, 2021